Description
Azelnidipine is a dihydropyridine L-type Ca2+ channel blocker that exhibits antihypertensive, anti-atherosclerotic, and anti-inflammatory activities. Clinically, azelnidipine decreases blood pressure; it also decreases inflammatory cytokine levels and carotid intima-media thickness. Additionally, this compound preserves insulin signaling and glucose uptake in animal models of oxidative stress.
References
Tawaramoto K, Kaneto H, Hashiramoto M, et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr. 2015 Sep 17;7:80. PMID: 26388951.
Tatsumi F, Kaneto H, Hashiramoto M, et al. Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes. Endocr J. 2015;62(8):741-7. PMID: 26073866.
Chen BL, Zhang YZ, Luo JQ, et al. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015 Feb 24;11:309-18. PMID: 25750535.